The Therapeutic Potential of MicroRNAs Delivered By Mesenchymal Stem Cells in Parkinson's Disease, Alzheimer's Disease, and Stroke: A Systematic Review of Preclinical Studies.
Dominika Przywara, Alicja Petniak, Paulina Gil-Kulik
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated 37 preclinical studies on the therapeutic potential of mesenchymal stem cells (MSCs) and their derived microRNAs (miRNAs) in Parkinson's disease, Alzheimer's disease, and stroke. The findings suggest that specific miRNAs, such as miR-133b and miR-146a, significantly improve neuroprotection and motor and cognitive outcomes by modulating gene expression and reducing neuroinflammation and apoptosis.
Key findings
- MSCs-derived miRNAs significantly modulate gene expression and reduce neuroinflammation.
- Specific miRNAs like miR-133b and miR-146a showed neuroprotective effects in animal models.
- Targeted delivery of these miRNAs improved motor and cognitive outcomes.
- The review included 37 preclinical studies across PD, AD, and stroke.
Why it matters
The increasing prevalence of neurological disorders highlights the urgent need for disease-modifying treatments. This review underscores the potential of MSCs-derived miRNAs as a novel therapeutic strategy, which could lead to significant advancements in the management of these conditions.